Article Figures & Data
Tables
Etiology Unknown Cryptogenic Symptomatic Total Gender Male 4 (7.5) 2 (3.7) 18 (34) 24 (45.2) Female 4 (7.5) 5 (9.5) 20 (37.8) 29 (54.8) Age at onset of spasms (months) 7.8 8.0 7.4 7.8 Age at start of treatment (months) 8.5 9.6 8.8 9.0 Delay in treatment (months) 0.72 1.6 1.4 1.3 Etiology n (%) Unknown 8 (15.1) Cryptogenic 7 (13.2) Symptomatic 38 (71.7) Perinatal asphyxia 9 (17) CNS malformation 10 (18.9) Tuberous sclerosis 5 (9.4) Metabolic 3 (5.7) Chromosomal anomaly 5 (9.4) Hypomelanosis of Ito 2 (3.8) Other 4 (7.5) Total 53 (100.0) Measurement Epilepsy Motor Cognitive Good outcome Poor outcome P-value Good outcome Poor outcome P-value Good outcome Poor outcome P-value Etiology 0.314 0.003* 0.001* Unknown 7 (13.2) 1 (1.9) 7 (13.2) 1 (1.9) 7(13.2) 1 (1.9) Cryptogenic 4 (7.5) 3 (5.7) 2 (3.8) 5 (9.4) 1 (1.9) 6 (11.3) Symptomatic 24 (45.3) 14 (26.4) 9 (17) 29 (54.7) 7 (13.2) 31 (58.5) Gender 0.502 0.502 0.272 Male 17 (70.8) 7 (29.2) 7 (70.8) 17 (29.2) 5 (20.8) 19 (79.2) Female 18 (62.0) 11 (38.0) 11 (38.0) 18 (62.0) 10 (34.5) 19 (65.5) Age at onset of spasms (months) 6.30 10.20 0.138 7.39 7.63 0.898 6.87 7.82 0.628 Delay in treatment (months) 0.82 1.64 0.116 0.44 1.41 0.010* 0.40 1.36 0.006* ↵* Statistically significant
Initial therapy n (%) ACTH/Prednisolone 6 (11.32) Vigabatrin 18 (33.96) Combination therapy 20 (37.73) ACTH/Prednisolone/Vigabatrin + Other 9 (16.98) Response to treatment Good Epilepsy Outcome Good Motor Outcome Good Cognitive Outcome ACTH/Prednisolone 4 (8.3) 1 (2.1) 0 (0) Vigabatrin 13 (20.8) 9 (10.4) 5 (8.3) Combination therapy 16 (33.3) 9 (18.8) 7 (14.6) ACTH/Prednisolone/Vigabatrin + Other 3 (4.2) 1 (2.1) 2 (2.1)
In this issue
Neurodevelopmental and epilepsy outcomes of patients with infantile spasms treated in a tertiary care center
